The 2016 multicenter DANISH trial questioned whether or not the implantable cardioverter-defibrillator (ICD) ought to be routinely really helpful in nonischemic systolic coronary heart failure (HF). The trial noticed no total survival benefit of ICD remedy, however hinted extra focused strategy to choosing sufferers for units is likely to be more practical.
Now a DANISH substudy raises its personal questions in regards to the usefulness of a typical check many consider can information such a focused strategy.
In a single-center cohort from the trial, proof of myocardial fibrosis by late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) imaging predicted all-cause mortality, according to plenty of earlier proof.
However such indicators of myocardial scarring, which proof suggests can promote ventricular arrhythmias, didn’t additionally predict improved survival with ICDs — which may solely occur by way of prevention of arrhythmic dying.
That LGE did not predict ICD profit “means that the elevated threat related to LGE isn’t altered by ICD implantation and that the mechanism for elevated mortality in these sufferers isn’t primarily shockable ventricular arrhythmias,” notes the DANISH subanalysis report, revealed December 24 within the American Coronary heart Journal.
The findings are solely suggestive, given the small dimension of the research. Nonetheless, they’re in line with LGE on CMR imaging as “a marker of total illness severity and all-cause mortality, as discovered beforehand, however not for shockable arrhythmic dying,” write the authors, led by Marie Bayer Elming, MD, PhD, Rigshospitalet, Copenhagen.
There was a lot hope that LGE would enhance the collection of sufferers with nonischemic coronary heart failure who may profit from ICD implantation; “nonetheless, our research doesn’t help this hope,” Elming informed theheart.org | Medscape Cardiology.
“There have been only a few sudden-cardiac-death (SCD) occasions, and due to this fact the information usually are not ample to conclude whether or not LGE can be utilized for SCD threat stratification,” she mentioned by electronic mail.
The evaluation included 236 sufferers with analyzable LGE on CMR scans at one DANISH heart, a subgroup of the overall cohort of 1116 sufferers with nonischemic HF and a left ventricular ejection fraction (LVEF) of 35% or decrease who had been randomized to medical remedy with or with out an ICD.
In adjusted evaluation, the chance for dying from any trigger, the first finish level, was considerably elevated over a median 5.three years for sufferers who confirmed LGE at CMR (hazard ratio [HR], 1.82; 95% CI, 1.002 – three.29; P = .049).
However such threat was not considerably completely different between ICD recipients and people with out units, amongst each the 113 sufferers with LGE by CMR and, individually, the 123 with out the CMR signal of fibrosis, no matter whether or not the sufferers had been additionally receiving cardiac resynchronization remedy (CRT).
The adjusted threat for a secondary arrhythmic finish level (a composite of sudden cardiac dying, resuscitated cardiac arrest, sustained ventricular tachycardia, and acceptable ICD shock) was greater than doubled in sufferers with LGE by CMR (HR, 2.23; 95% CI, 1.12 – four.47; P = .02).
“There is definitely plenty of knowledge that areas of scar in sufferers with nonischemic cardiomyopathy might be the supply of ventricular arrhythmias, so it is smart that if scar is detectable by magnetic resonance imaging, it ought to be related to an elevated threat of arrhythmias,” William G. Stevenson, MD, not related to DANISH, informed theheart.org | Medscape Cardiology.
And, “we have lengthy acknowledged that ventricular arrhythmias are markers of elevated whole mortality and elevated threat of coronary heart failure hospitalizations,” mentioned Stevenson, from Vanderbilt College Medical Middle, Nashville, Tennessee. “It is not a shock, then, as has been properly proven, that scar is related to a rise in mortality.”
Subsequently, using LGE by CMR to determine sufferers with nonischemic systolic HF most certainly to profit from ICDs “would appear to be an affordable strategy that must be examined.”
So the outcomes of the present research “are a bit stunning in that regard, as a result of I’d have anticipated to see extra profit within the sufferers who’ve scar,” he mentioned.
“I feel the research is underpowered to have the ability to present a good thing about the defibrillator,” he added. Scar was certainly associated to arrhythmic threat, “it simply wasn’t related to a excessive sufficient threat on this comparatively smaller variety of sufferers to the place a defibrillator might be proven to be helpful.”
Additionally, they had been at elevated threat for each arrhythmic and nonarrhythmic mortality, and “whenever you give them a defibrillator, you are not doing something to handle the nonarrhythmic causes of dying,” Stevenson mentioned.
“That is, I feel, an indication of an exquisite success story — that with current remedy for coronary heart failure and cardiomyopathy, and with resynchronization remedy, survival has gotten higher and sudden dying charges have fallen. However that makes it very onerous to point out a profit on this inhabitants from a remedy that solely addresses arrhythmias.”
DANISH was supported by Medtronic and St. Jude Medical. Elming declares she has no conflicts of curiosity. Disclosures for the opposite authors are within the report. Stevenson has beforehand disclosed receiving analysis grants from Novartis, consulting or serving on an advisory board for Abbott, and journey bills or meals from Novartis and St. Jude Medical.
Am Coronary heart J. Printed on-line December 24, 2019. Summary
Comply with Steve Stiles on Twitter: @SteveStiles2. For extra from theheart.org | Medscape Cardiology, comply with us on Twitter and Fb.